We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

  Gold Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Dec 2020 - 08 Dec 2020
Virtual Venue

Serum Creatinine-to-Cystatin C Ratio Predicts AKI Mortality

By LabMedica International staff writers
Posted on 05 Nov 2020
Print article
Image: The N Latex Cystatin C is a latex-enhanced immunonephelometry assay.  The serum Creatinine-to-Cystatin C ratio predicts acute kidney injury mortality (Photo courtesy of Siemens Healthineers).
Image: The N Latex Cystatin C is a latex-enhanced immunonephelometry assay. The serum Creatinine-to-Cystatin C ratio predicts acute kidney injury mortality (Photo courtesy of Siemens Healthineers).
Acute kidney injury (AKI) is a common and serious complication among critically ill patients and often requires continuous renal replacement therapy (CRRT). Owing to the high mortality risk associated with kidney injury development, identifying effective risk factors for outcome is imperative in AKI patients being treated with CRRT.

Creatinine is mainly released from muscle tissue, and therefore its serum concentration is influenced by whole body muscle mass. Cystatin C, on the other hand, is universally produced by nucleated cells. Both creatinine and cystatin are commonly measured to estimate kidney function. Under situations of kidney injury, creatinine and cystatin C exhibit variable kinetics and their levels may vary rapidly.

Nephrologists at Yonsei University College of Medicine (Seoul, Republic of Korea) studied 1,588 patients who underwent CRRT in a single tertiary center intensive care unit between August 2009 and June 2019. The mean age was 64.7 ± 14.5 years and 635 patients (40.0%) were female. Among all subjects, 886 (55.8%) had hypertension and 597 (37.6%) were being treated for diabetes mellitus.

The scientists collected laboratory data included complete blood cell counts, serum blood urea nitrogen (BUN) levels, creatinine and cystatin C, albumin, and electrolytes. Serum creatinine levels were determined using an isotope dilution mass spectrometry-traceable method at a central laboratory, and cystatin C levels were measured by immunonephelometry, with calibration against the reference. The ratio of creatinine (mg/dL) to cystatin C (mg/L) was calculated from values measured concomitantly at baseline.

The investigators reported that the range of creatinine:cystatin C ratio was 0.08-10.48. The 30- and 90-day mortality rates were significantly lower for the higher creatinine:cystatin C ratio groups. Multivariable Cox proportional hazards regression analyses revealed that the mortality risk decreased successively across quartiles of increasing creatinine:cystatin C ratio. When creatinine:cystatin C ratio was evaluated using cubic spline analyses, the risks for both 30- and 90-day mortality were lower with higher creatinine:cystatin C ratios. These associations remained significant even after adjustment for confounding variables. A total of 954 (60.1%) and 1,055 (66.4%) deaths occurred within 30 and 90 days of CRRT initiation, respectively.

The authors concluded that the creatinine:cystatin C ratio is associated with survival in ICU patients with AKI undergoing CRRT. This ratio may be used as a practical prognosis risk American Journal of Kidney Diseases.




Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.